AdaptHealth CEO granted 329,449 restricted stock units

AdaptHealth Corp. Chief Executive Officer and director Suzanne Foster reported an award of 329,449 shares of common stock on January 30, 2026.

Rhea-AI Filing Summary

AdaptHealth Corp. Chief Executive Officer and director Suzanne Foster reported an award of 329,449 shares of common stock on January 30, 2026. The filing explains these shares are restricted stock units that will be settled in common stock when they vest, effectively tying compensation to future service or performance.

After this grant, Foster directly beneficially owns 924,050 shares of AdaptHealth common stock. The transaction price is shown as $0 per share, consistent with a stock-based compensation grant rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 329,449 shares

Grant/Award 1 txn

Insider Foster Suzanne

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	329,449	$0.00	$0.00

Holdings After Transaction: Common Stock — 924,050 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units and will be settled in common stock upon vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 4 for AdaptHealth (AHCO) show about Suzanne Foster?

The Form 4 shows CEO Suzanne Foster received a large stock-based award. She reported 329,449 restricted stock units granted on January 30, 2026, which will be settled in AdaptHealth common stock upon vesting as part of her equity compensation.

How many AdaptHealth (AHCO) shares did Suzanne Foster report acquiring?

Suzanne Foster reported acquiring 329,449 shares in the form of restricted stock units. These units are scheduled to settle in AdaptHealth common stock once vesting conditions are met, increasing her direct beneficial ownership reported after the transaction to 924,050 common shares.

What type of equity did AdaptHealth (AHCO) grant to CEO Suzanne Foster?

The grant to Suzanne Foster consists of restricted stock units (RSUs). The filing states these RSUs represent shares that will be settled in AdaptHealth common stock upon vesting, meaning she receives the underlying shares only after vesting requirements are satisfied.

How did Suzanne Foster’s AdaptHealth (AHCO) share ownership change after the grant?

After the reported RSU grant, Suzanne Foster beneficially owns 924,050 shares. This figure reflects her direct AdaptHealth common stock holdings following the award of 329,449 restricted stock units that are scheduled to convert into shares once they vest.

What transaction price was reported for Suzanne Foster’s AdaptHealth (AHCO) share award?

The transaction lists a price of $0 per share for the 329,449 units. This indicates the award is stock-based compensation, not a market purchase, with value realized as the restricted stock units vest into AdaptHealth common stock over time.

What is Suzanne Foster’s role at AdaptHealth (AHCO) according to the filing?

The filing identifies Suzanne Foster as both a director and Chief Executive Officer. Her dual role as CEO and board member means the reported restricted stock unit grant directly links a portion of her compensation to AdaptHealth’s future equity performance through common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 08:18 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Suzanne

(Last) (First) (Middle)

C/O ADAPTHEALTH LLC

555 EAST NORTH LANE, SUITE 5075

(Street)

CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		329,449(1)	A	$0	924,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units and will be settled in common stock upon vesting.

Remarks:

*** The Power of Attorney given by the reporting person was previously filed with the U.S. Securities and Exchange Commission on February 4, 2025 as an exhibit to the Form 4 filed by the reporting person with respect to the Issuer and is hereby incorporated by reference.

	/s/ Richard Rew, as attorney-in-fact for Suzanne Foster	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.